Larimar Therapeutics, Inc. — Director's Dealing 2016

Jul 26, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2016-07-25

Reporting Person: Allen Patricia L (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-25	Common Stock	P	7800	$3.081	Acquired	11593	Direct
2016-07-26	Common Stock	P	8200	$3.15	Acquired	19793	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at a price ranging from $3.05 to $3.11, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at a price ranging from $3.10 to $3.16, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3: Includes 2,500 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on July 1, 2016; 200 shares acquired under the Plan on January 1, 2016; 585 shares acquired under the Plan on July 1, 2015; and 508 shares acquired under the Plan on January 1, 2015.